Wellmarker Bio signs worth of $528 mn tech transfer deal

The company enters agreement with European biotech firm for new drug candidate, planning Phase 1 clinical trial in Oct. 2023

Wellmarker Bio signs worth of 8 mn tech transfer deal
In-hyuk Park 2
2023-09-12 17:38:29 hyuk@hankyung.com
Bio & Pharma

Wellmarker Bio, South Korea's oncology drug development company, announced on Monday that it has signed a technology transfer agreement with a European biotech company for its immune checkpoint inhibitor candidate WM-A1-3389.

The latest contract, which includes upfront payments and staged milestones, amounts to 700 billion won ($528 million), with separate royalties. The company did not disclose the identity of the contracting party. With this agreement, Wellmarker Bio has granted exclusive global rights for the clinical development and commercialization of WM-A1-3389.

WM-A1-3389 is an immune checkpoint inhibitor that targets a previously undisclosed novel immune checkpoint, stimulating the anti-cancer immune pathway. The company received approval for a Phase 1 clinical trial from the Ministry of Food and Drug Safety in April. It plans to initiate the first dosing for Phase 1a in solid cancer patients next month.

The company received support from the Ministry of Health and Welfare's New Drug Development Task Force and the follow-up project, National New Drug Development Project, for non-clinical stages. This contract was signed in collaboration with the UK-based agency PharmaVentures.

"As an unlisted bio company, achieving large-scale technology transfer in Europe is significant," CEO of Wellmarker Bio Jin Dong-Hoon said. "Through this agreement, we will grow into a specialized company in anti-cancer drugs with global competitiveness."

Wellmarker Bio is the first spin-off company from Asan Medical Center. It is developing innovative drugs based on biomarkers for predicting treatment responses using its core technology, a novel target discovery system. Currently, it has two drug candidates in Phase 2 clinical stages and two in non-clinical stages under development.

The WM-A1-3389 technology, exported this time, is under development as a treatment for non-small cell lung cancer. Another colorectal cancer-targeted therapy candidate, "WM-S1-030," is undergoing Phase 1 clinical trials in South Korea and Australia.

Wellmarker Bio applied for a technical evaluation for a special listing on the KOSDAQ market with the Korea Exchange on Sept. 11, aiming for listing on the KOSDAQ market in the first half of next year.

Write to In-hyuk Park at hyuk@hankyung.com
#Wellmarker Bio #technology transfer agreement #immune checkpoint inhibitor #WM-A1-3389 #WM-S1-030 #colorectal cancer

Celltrion to cut biosimilar development costs with data bank

Celltrion to cut biosimilar development costs with data bank

Celltrion Chairman Seo Jin-seok presents Korean Invsestment Week 2023 on Sept. 12 The use of data and computing is a new paradigm in the biopharmaceutical industry, reducing the new drug development time and cost, Celltrion Inc. Chairman Seo Jin-seok said on Tuesday.“We are building an in

AriBio applies for Phase 3 clinical trials in China for oral dementia drug

AriBio applies for Phase 3 clinical trials in China for oral dementia drug

South Korean clinical-stage biotech company AriBio Co. on Thursday said it applied for Phase 3 clinical trials on the anti-Alzheimer's candidate treatment AR1001 with the Center for Drug Evaluation of China's National Medical Products Administration.Tests on AR1001 in China will be done on a

Yungjin Pharm's new drug candidate gets Fast Track from FDA

Yungjin Pharm's new drug candidate gets Fast Track from FDA

South Korea's Yungjin Pharm has secured Fast Track designation from the US Food and Drug Administration (FDA) for its new drug candidate KL1333, designed to treat rare and severe primary mitochondrial diseases. The FDA's nod coincides with encouraging phase 2/3 clinical trials, bolstering Swed

Hanmi Pharm to start global clinical trials for immune-oncology drug

Hanmi Pharm to start global clinical trials for immune-oncology drug

South Korea's Hanmi Pharmaceutical Co. announced on Tuesday that it has received approval for the phase 1 clinical trial plan of the immune-oncology drug BH3120, which is being jointly developed with its Chinese subsidiary Beijing Hanmi Pharm by the Korean Ministry of Food and Drug Safety.Hanm

ABL Bio gets OK for phase 1 clinical trials for immune-oncology drug

ABL Bio gets OK for phase 1 clinical trials for immune-oncology drug

New drug development company ABL Bio Inc. announced on Thursday that it has received approval from the Ministry of Food and Drug Safety of South Korea for the domestic phase 1 clinical trial plan of the bispecific antibody immune-oncology drug ABL103.As a result, the company will proceed with

(* comment hide *}